ClinicalTrials.gg
CompletedNCT01001572Updated May 24, 2011Results posted

Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension

A Phase 3 interventional study of Valsartan/amlodipine 160/5 mg and Valsartan 160 mg in Essential Hypertension, sponsored by Novartis. Completed at 2 sites. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-05-24.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
932
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies in Essential Hypertension by Novartis — none open to participants now, none under way, none of them phase 3. Essential Hypertension · Novartis.

Enrollment
6th of 25
932 · median 506
Started
2009
with 2 others
Phase 3
15 of 27
none open now
Registered
11th of 27
by date

Among the 27 studies in Essential Hypertension by Novartis, this one is the 6th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2009, is one of 15 in phase 3, and was the 11th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

None of the 27 studies in Essential Hypertension by Novartis is open now. The open studies under Essential Hypertension, anywhere →

Who these studies take

Of the 44 Essential Hypertension studies recruiting now, 16 (36%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies in Essential Hypertension by Novartis as a file.
02

Study summary

This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP ≥90 mmHg and \<110 mmHg) on valsartan 160 mg alone.

03

Conditions studied

  • Essential Hypertension

Keywords

  • Blood pressure
  • hypertension
  • Exforge
  • valsartan/amlodipine
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must give written
  • Male or female ages 18 or older and less than 86 years
  • Diagnosed as having essential diastolic hypertension, as follows:

    • Visit 2/Single-blind run-in entry, all participants MUST have a MSDBP ≥ 95 mmHg and \< 100 mmHg
    • At Visit 3/Core double-blind treatment period entry, all patients MUST have a MSDBP >=90 mmHg and \<110 mmHg

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension
  • Evidence of secondary form of hypertension (coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma or polycystic kidney disease )
  • Malignant hypertension
  • Administration of any agent indicated for the treatment of hypertension after Visit 1
  • Known moderate or malignant retinopathy.
  • Known or suspected , including history of allergy or to Angiotensin II Receptor Blockers (ARBs), Calcium Channel Blockers (CCBs), or to drugs with similar chemical structures
  • History of hypertensive encephalopathy, cerebrovascular accident, or , myocardial infarction or all types of revascularization, angina pectoris of any type, including unstable angina
  • History of heart failure Grade II-IV according to (NYHA) classification
  • Second of third degree heart block regardless of the use of a pacemaker, concomitant potentially life-threatening arrhythmia or symptomatic arrhythmia

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
932 participants (actual)

Study arms

  • Active comparator
    Valsartan 160 mg

    One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks

    Drug: Valsartan 160 mg · Drug: Placebo

  • Experimental
    Valsartan/amlodipine 160/5 mg

    One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks

    Drug: Valsartan/amlodipine 160/5 mg · Drug: Placebo

  • Other
    Single-Blind Run-In Valsartan 160 mg

    Single-Blind Run-In treatment with one capsule Valsartan 160 mg taken orally once daily at approximately 9:00 AM for 4 weeks.

    Drug: Valsartan 160 mg

Interventions

  • DrugValsartan/amlodipine 160/5 mg

    Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.

    Also known as: Exforge® 160/5mg

  • Valsartan 160 mg capsule taken orally once daily.

    Also known as: Diovan® 160mg

  • DrugPlacebo

    1 capsule or tablet taken orally once daily

06

What researchers measure

Primary outcomes

  1. Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint

    Three arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and center (pooled as appropriate) as factors and centered baseline MSDBP as a covariate.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to Week 8 Endpoint

    Three arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and center (pooled as appropriate) as factors and centered baseline MSSBP as a covariate

    Time frame: Baseline and Week 8

  2. Percentage of Participants With a Diastolic Blood Pressure Response at 8 Week Endpoint

    The percentage of participants with a Diastolic Blood Pressure Response defined as the percentage of participants with a Mean Sitting Diastolic Blood Pressure (MSDBP) \< 90 mmHg or a \>= 10 mmHg reduction from baseline.

    Time frame: Baseline and Week 8

  3. Percentage of Participants With Diastolic Blood Pressure Control at 8 Week Endpoint

    The percentage of participants with Diastolic Blood Pressure Control defined as the percentage of participants with a Mean Sitting Diastolic Blood Pressure (MSDBP) \< 90 mmHg.

    Time frame: Week 8

  4. Percentage of Participants With Overall Blood Pressure Control at 8 Week Endpoint

    The percentage of participants with Overall Blood Pressure Control defined as the percentage of participants with a Mean Sitting Systolic Blood Pressure (MSSBP)/Mean Sitting Diastolic Blood Pressure (MSDBP) \< 140/90 mmHg.

    Time frame: Week 8

07

Results

Posted May 24, 2011

Participant flow

932 participants were entered into the single-blind valsartan 160 mg arm. 278 participants were discontinued from the single-blind arm. 654 participants were randomized into the double-blind treatment phase; 329 to the Valsartan/amlodipine arm and 325 to the valsartan alone arm.

Single-Blind Valsartan 160 mg
Participant flow — Single-Blind Valsartan 160 mg
MilestoneSingle-Blind Run -In Valsartan 160 mgValsartan/Amlodipine 160/5 mgValsartan 160 mg
Started93200
Completed65400
Not completed27800
Withdrew: Withdrawal by subject3200
Withdrew: Adverse event1100
Withdrew: Abnormal test procedure result(s)9600
Withdrew: Unsatisfactory therapeutic effect700
Withdrew: Abnormal laboratory value100
Withdrew: Lost to follow-up400
Withdrew: Administrative problems8200
Withdrew: Condition no longer requires study drug4500
Double-Blind Treatment Phase
Participant flow — Double-Blind Treatment Phase
MilestoneSingle-Blind Run -In Valsartan 160 mgValsartan/Amlodipine 160/5 mgValsartan 160 mg
Started0329325
Full analysis set (fas)0328323
Completed0319306
Not completed01019
Withdrew: Adverse event022
Withdrew: Withdrawal by subject0813
Withdrew: Abnormal test procedure result(s)001
Withdrew: Unsatisfactory therapeutic effect001
Withdrew: Protocol deviation001
Withdrew: Lost to follow-up001

Outcome measures

PrimaryChange in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint

Three arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and center (pooled as appropriate) as factors and centered baseline MSDBP as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mmHg
Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint
mmHgValsartan/Amlodipine 160/5 mgValsartan 160 mg
Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint-10.3 ± 0.39-6.6 ± 0.40
SecondaryChange in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to Week 8 Endpoint

Three arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSSBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and center (pooled as appropriate) as factors and centered baseline MSSBP as a covariate

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mmHg
Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to Week 8 Endpoint
mmHgValsartan/Amlodipine 160/5 mgValsartan 160 mg
Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to Week 8 Endpoint-14.9 ± 0.61-7.0 ± 0.61
SecondaryPercentage of Participants With a Diastolic Blood Pressure Response at 8 Week Endpoint

The percentage of participants with a Diastolic Blood Pressure Response defined as the percentage of participants with a Mean Sitting Diastolic Blood Pressure (MSDBP) \< 90 mmHg or a \>= 10 mmHg reduction from baseline.

Time frame:
Baseline and Week 8
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Diastolic Blood Pressure Response at 8 Week Endpoint
Percentage of ParticipantsValsartan/Amlodipine 160/5 mgValsartan 160 mg
Percentage of Participants With a Diastolic Blood Pressure Response at 8 Week Endpoint70.152.6
SecondaryPercentage of Participants With Diastolic Blood Pressure Control at 8 Week Endpoint

The percentage of participants with Diastolic Blood Pressure Control defined as the percentage of participants with a Mean Sitting Diastolic Blood Pressure (MSDBP) \< 90 mmHg.

Time frame:
Week 8
Reported as:
Number · Percentage of Participants
Percentage of Participants With Diastolic Blood Pressure Control at 8 Week Endpoint
Percentage of ParticipantsValsartan/Amlodipine 160/5 mgValsartan 160 mg
Percentage of Participants With Diastolic Blood Pressure Control at 8 Week Endpoint65.950.8
SecondaryPercentage of Participants With Overall Blood Pressure Control at 8 Week Endpoint

The percentage of participants with Overall Blood Pressure Control defined as the percentage of participants with a Mean Sitting Systolic Blood Pressure (MSSBP)/Mean Sitting Diastolic Blood Pressure (MSDBP) \< 140/90 mmHg.

Time frame:
Week 8
Reported as:
Number · Percentage of Participants
Percentage of Participants With Overall Blood Pressure Control at 8 Week Endpoint
Percentage of ParticipantsValsartan/Amlodipine 160/5 mgValsartan 160 mg
Percentage of Participants With Overall Blood Pressure Control at 8 Week Endpoint61.339.3

Adverse events

Collected over Week 8. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valsartan/Amlodipine 160/5 mg—0/329 (0%)0/329 (0%)
Valsartan 160 mg—1/325 (0.3%)0/325 (0%)
Most frequent serious events
Most frequent serious events
EventValsartan/Amlodipine 160/5 mgValsartan 160 mg
Uterine polypReproductive system and breast disorders0/3291/325

Baseline characteristics

Age Continuous
Age Continuous(years)Valsartan/Amlodipine 160/5 mgValsartan 160 mgTotal
Mean52.9 ± 9.4753.1 ± 9.4153.0 ± 9.43
Sex: Female, Male
Sex: Female, Male(Participants)Valsartan/Amlodipine 160/5 mgValsartan 160 mgTotal
Female141150291
Male187173360
08

Study locations

2 sites
  • Investigative site in Romainia
  • Novartis Investigative Site
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2009
First posted
Oct 26, 2009
Start
Sep 2009
Primary completionActual
May 2010
CompletionActual
May 2010
Results first posted
May 24, 2011
Last update
May 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01001572
Lead sponsor
Novartis
First posted
Oct 26, 2009
Start date
Sep 2009
Primary completion
May 2010
Completion
May 2010
Results posted
May 24, 2011
Last update
May 24, 2011

Study contacts

Novartis Pharmaceuticals
study director · Sponsor GmbH
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion